Overview

GPS Compared With BAT in AML CR2/CR2p

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

To assess the safety and efficacy of galinpepimut-S compared with investigator's choice of best available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second complete remission 2 (CR2)/second complete remission with incomplete platelet recovery (CR2p).

Phase:

Phase 3

Details

Lead Sponsor:

Sellas Life Sciences Group

Treatments:

Azacitidine
Cytarabine
Decitabine
Venetoclax